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Myocardial Perfusion Imaging Using Ultrasound
Contrast Agents
Now or Never?*
Flordeliza S. Villanueva, MD
Pittsburgh, PennsylvaniaUltrasound contrast agents (UCAs) have been in
the echocardiographic “toolbox” for many years.
Two such agents (Definity [Lantheus Medical Im-
aging, North Billerica, Massachusetts] and Optison
[GE Healthcare, Princeton, New Jersey]) are ap-
proved by the U.S. Food and Drug Administration
(FDA) and are commercially available for left ven-
tricular cavity opacification in patients with techni-
cally difficult echocardiograms. The greater, still
unrealized value of these unique erythrocyte tracers,
however, resides in their ability to depict the spatial
distribution of myocardial perfusion and to quantify
intramyocardial blood volume, properties that ren-
der UCAs ideal for the detection and localization of
coronary artery disease (CAD).
See page 934
UCAs have had a checkered history, particularly
with respect to myocardial perfusion imaging. The
literature is replete with studies showing the prom-
ise of myocardial contrast echocardiography
(MCE) for CAD detection (1,2). Studies in dogs
dating back to the early 1980s hinted at the poten-
tial of UCAs for echocardiographic assessment of
myocardial perfusion (3). Subsequent milestones
included the development of second-generation
UCAs capable of transpulmonary transit (1), place-
ment of sophisticated UCA detection strategies on
ultrasound imaging systems (4), and animal studies
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
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vascular Imaging or the American College of Cardiology.
From the Center for Ultrasound Molecular Imaging and Therapeutics,
Cardiovascular Institute, University of Pittsburgh, Pittsburgh, Penn-
sylvania. Dr. Villanueva has reported that she has no relationships to
disclose.proving the principle that MCE can measure in-
tramyocardial blood volume and hence detect CAD
during stress testing (5,6). In 1997, Kaul et al. (7)
ushered in what was viewed by many to be a bright
new era for MCE, demonstrating in humans the
concordance between stress MCE and single-
photon emission computed tomography images.
This perception of a bright future was exemplified
by a surge of publications in this area, alongside
industry efforts to achieve FDA approval for new
UCAs developed specifically for MCE (1,2).
Then, in October 2007, the FDA mandated
product labeling revisions for Definity and Optison
that included a “black box” warning that cited safety
concerns, extended monitoring requirements for all
patients, and new contraindications (8). Around
this same time period, 2 companies (Point Biomed-
ical Corp. [San Carlos, California] and Acusphere
Inc. [Cambridge, Massachusetts]) with New Drug
Applications for UCAs (Cardiosphere and Imagify,
respectively) failed to receive FDA approval, with
the execution of FDA recommendations for addi-
tional clinical trials proving to be financially insur-
mountable; currently, clinical trials to commercially
develop UCAs for MCE have ceased in the U.S.
Such events raised serious questions about the
future of MCE.
Subsequent multicenter analyses of records re-
flecting 200,000 patients receiving UCAs con-
firmed their relative safety in a range of clinical
settings (9–12). In July 2008, the FDA relaxed its
relabeling mandate, reducing the monitoring re-
quirements and narrowing the contraindications to
UCAs (13). More recently, there seems to be
renewed industry effort in pursuing approval of
UCAs for the myocardial perfusion indication in
Europe, and efforts in the U.S. have been initiated
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945y another UCA manufacturer (Bracco Diagnos-
ics, Milan, Italy) to pursue perfusion imaging—
lbeit of the liver—in radiologic indications.
Optimists might interpret these recent develop-
ents as the early markers of a resurgence of UCAs,
hich could even culminate in the clinical imple-
entation of MCE. Against this historical back-
rop, the study by Arnold et al. (14) in this issue of
JACC is a timely contribution to what could be a
eascendancy of MCE. This study evaluated the
iagnostic accuracy of adenosine stress MCE in a
mall cohort of intermediate-risk patients scheduled
or coronary angiography. The truth standard for
oronary anatomy and physiology were cardiac
atheterization and high field strength (3-T) perfu-
ion cardiac magnetic resonance (CMR), respec-
ively. Although it can be argued that CMR and
CE are inherently not comparable because the
ormer uses a diffusible tracer (gadolinium), whereas
he latter uses an intravascular probe, let us accept
he premise of comparability. The diagnostic accu-
acy of MCE for angiographic 50% coronary
tenosis was 82%, with a respectable sensitivity of
5% and specificity of 76%, values that were statis-
ically no different from those of CMR. Further-
ore, MCE and CMR were comparable in diag-
ostic accuracy for identifying the extent and
ocation of angiographic CAD. MCE had 85%
ensitivity, 74% specificity, and 79% diagnostic
ccuracy for detection of CMR-defined inducible
schemia, and 87% diagnostic accuracy for detecting
nducible ischemia on a per-vessel basis.
Of note, inducible ischemia was detected by
MR in 11% of segments, which was significantly
igher than the 7% detected by MCE, suggesting
hat MCE may underestimate total ischemic bur-
en. Whether this underestimation was more prev-
lent in particular vascular territories than others is
ot reported, nor is the concordance between CMR
nd MCE on a per-vessel or per-segment basis
rovided, likely because of small patient numbers.
lso notable is that despite the good diagnostic
ccuracy of MCE for predicting angiographic dis-
ase on a per-patient basis, there was a strong trend
or MCE to lag behind CMR in its sensitivity for
etecting multivessel disease, although, conversely,
ts specificity exceeded that of CMR in this cate-
ory. MCE might have performed better had the
uthors used flash-replenishment imaging because
egmental differences in replenishment time could
ignal CAD despite apparently homogeneous peak
ideointensities (2). Also, despite efforts to create a
atient cohort with an intermediate likelihood of oAD based on the inclusion/exclusion criteria, the
eferral bias inherent in a study population under-
oing cardiac catheterization should caution us in
pplying these data to populations with a lower
re-test probability of CAD.
Limitations notwithstanding, this study reasserts
he potential of MCE to be a useful diagnostic tool.
he study reminds us to consider whether the time
ay be ripe to relaunch a concerted effort to move
CE into the clinical arena. The landscape has
hanged, such that the time may be more auspicious
han before for such an effort to take place, for at
east 3 reasons. First, there is heightened concern
bout excess cancers resulting from exposure to
ontrivial levels of ionizing radiation resulting from
ontemporary medical imaging practices, as recently
utlined by the FDA (15) and others (16). Second,
ignificant shortages in the radioisotope technetium-
9m, which is used in 97% of patients undergoing
uclear stress testing, have recently developed due
o the tenuous status of 2 (of only 5 worldwide)
uclear reactors that supply most of the world’s
olybdenum-99, the precursor of technetium-99m
17). Third, other promising indicators of MCE’s
ossible turn-of-fortune include the revision of the
DA black box warning (13) and greater interac-
ion between echocardiographers and the FDA,
uch that both parties are vastly more informed of
ach others’ concerns than was previously the case.
dditionally, as has always been true, MCE offers
ractical advantages of simpler instrumentation, less
xpense, and portability.
So, have the stars finally lined up for MCE’s
uture? Is it “now or never” for MCE to make its big
reak into clinical practice? If the answers to these
uestions are “yes,” what will it take to move
orward? Of course, an agent approved for MCE by
he FDA should exist—a tall order that is, however,
ot impossible to achieve. But is that all there is to
t? Unlikely. It is too easy to place blame on the
DA, industry, or reimbursement issues for the lack
f clinical maturation of MCE. It should be noted
hat even when Definity or Optison are used for the
DA-approved and reimbursable indication of ven-
ricular opacification, their concurrent, no-added-
ost usage for perfusion imaging, albeit off label, has
ot been adopted by clinicians. Gadolinium-
iethylenetriaminepentaacetic acid is not FDA ap-
roved for CMR perfusion imaging, yet ironically it
as the gold standard in the present study, suggest-
ng that FDA approval of UCAs, although impor-
ant, is not the sole prerequisite to clinical adoption
f MCE.
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946Beyond FDA approval, for MCE to “happen,”
here needs to be buy-in by the clinicians them-
elves; we need to decide, as the community of
magers, whether to learn MCE imaging, much in
he same way that clinicians make the conscious
ecision to train in coronary computed tomography
ngiography or CMR. It is naïve to think that
igh-quality MCE can be performed with the
imple turn of a switch; there is a learning curve that
ust be traveled. Without the commitment of
linicians to learn and use MCE, it is unlikely that
CA companies will see value in expending re-
ources to achieve FDA approval for myocardial
erfusion imaging.
Despite the recent setbacks for UCAs and MCE,Alert. Micro-bubble Contrast Agents pension and Optechnology with great clinical promise. It affirms
hat many of us who have used MCE in patients
ave observed for years: it works. This study alerts
s that the time is propitious, perhaps more than
ver before, to move MCE beyond proof of concept
o a place where our patients can genuinely benefit
rom this imaging technology.
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